Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Aug 7;24(Suppl 5):V-1–V-5. doi: 10.1002/clc.4960241702

The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin‐converting enzyme inhibitors

Carl J Pepine 1,, Eileen M Handberg 1
PMCID: PMC6654867  PMID: 11712769

Abstract

Recent advances in the understanding of vascular disease genesis suggest that atherosclerosis and hypertension, primary targets of therapy in the INternational VErapamil SR/trandolapril STudy (INVEST), are closely related. A unified model for the development of cardiovascular disease (CVD) is emerging from recent advances related to atherosclerosis and hypertension. The process of vascular disease appears to begin early in life, when signs of endothelial dysfunction first appear. A primary cause of CVD progression is increased oxidative stress in the endothelium caused by multiple risk factor conditions, including heredity, dyslipidemia, smoking, diabetes, and elevated systolic blood pressure (SBP > 110 mmHg). The renin‐angiotensin and kallikrein‐kinin systems are important regulators of blood pressure and atherosclerosis. In the reninangiotensin system, angiotensin‐converting enzyme (ACE) mediates generation of angiotensin II (ang II) at local vascular sites and in the plasma and also degrades bradykinin. Information derived from INVEST will help to identify treatment strategies, such as those containing a calcium antagonist and an ACE inhibitor, that are targeted directly at the vascular disorder responsible for hypertension and atherosclerosis.

Full Text

The Full Text of this article is available as a PDF (474.5 KB).

References

  • 1. Hua C., Harrison DG, Endothelial dysfunction and cardiovascular disease: The role of oxidant stress. Circ Res 2000; 87: 840–844 [DOI] [PubMed] [Google Scholar]
  • 2. Ferrario CM, Martell N., Yunis C., Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A., Novikov SV, Pinillas C., Luque M., Characterization of angiotensin‐(1–7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 1998; 11: 137–146 [DOI] [PubMed] [Google Scholar]
  • 3. Iyer SN, Ferrario CM, Chappell MC, Angiotensin‐(1–7) contributes to the antihypertensive effects of blockade of the renin‐angiotensin system. Hypertension 1998; 31: 356–361 [DOI] [PubMed] [Google Scholar]
  • 4. Krebs LT, Hanesworth JM, Sardinia MF, Speth RC, Wright JW, Harding JW, A novel angiotensin analog with subnanomolar affinity for angiotensin‐converting enzyme. J Pharmacol Exp Ther 2000; 293: 260–267 [PubMed] [Google Scholar]
  • 5. Meng QC, Oparil S., Purification and assay methods for angiotensin‐converting enzyme. J Chromatogr A 1996; 743: 105–122 [DOI] [PubMed] [Google Scholar]
  • 6. Dzau VJ, Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047–1052 [DOI] [PubMed] [Google Scholar]
  • 7. Napoli C., D'Armiento FP, Mancini FP, Postiglione A., Witztum JL, Palumbo G., Palinski W., Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100: 2680–2690 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Panza JA, Quyyumi AA, Callahan TS, Epstein SE, Effect of antihypertensive treatment on endothelium‐dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21: 1145–1151 [DOI] [PubMed] [Google Scholar]
  • 9. Taddei S., Virdis A., Mattei P., Arzilli F., Salvetti A., Endothelium‐dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992: 20: S193–S195 [DOI] [PubMed] [Google Scholar]
  • 10. Nickenig G., Baumer AT, Temur Y., Kebben D., Jockenhovel F., Bohm M., Statin‐sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131–2134 [DOI] [PubMed] [Google Scholar]
  • 11. Wassmann S., Laufs U., Baumer AT, Muller K., Ahlbory K., Linz W., Itter G., Rosen R., Bohm M., Nickenig G., HMG‐CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450–1457 [DOI] [PubMed] [Google Scholar]
  • 12. Fukuhara M., Geary RL, Diz DI, Gallagher PE, Wilson JA, Glazier SS, Dean RH, Ferrario CM, Angiotensin‐converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35: 353–359 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES